# "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"

> **NCT07684326** · PHASE2,PHASE3 · RECRUITING · sponsor: **Beni-Suef University** · enrollment: 52 (estimated)

## Conditions studied

- Ascites Hepatic

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT07684326
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-07
- **Final completion:** 2027-09
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684326, ""Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07684326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*